Thiogenesis Therapeutics, Corp.
TTIPF
$0.58
$0.00-0.27%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 28.51% | 19.02% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.10% | 32.60% | |||
| Operating Income | -31.10% | -32.60% | |||
| Income Before Tax | -26.08% | -39.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.08% | -39.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.08% | -39.66% | |||
| EBIT | -31.10% | -32.60% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -16.89% | -38.32% | |||
| Normalized Basic EPS | -16.76% | -38.06% | |||
| EPS Diluted | -16.89% | -38.32% | |||
| Normalized Diluted EPS | -16.76% | -38.06% | |||
| Average Basic Shares Outstanding | 8.18% | 0.62% | |||
| Average Diluted Shares Outstanding | 8.18% | 0.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||